Thromboelastography versus bleeding time for risk of bleeding post native kidney biopsy

Area of Science:

• Nephrology
• Hematology
• Radiology

Background:

• Screening primary hemostasis before renal biopsy is crucial due to bleeding risks.
• The traditional bleeding time test (BT) is standard but its efficacy is debated.
• Thromboelastography (TEG) is a potential alternative, yet data in renal dysfunction is scarce.

Purpose of the Study:

• To evaluate TEG abnormalities and their clinical impact in patients undergoing native kidney biopsy.
• To compare TEG with bleeding time tests in patients with renal impairment.
• To assess the predictive value of TEG for bleeding complications post-renal biopsy.

Main Methods:

• Retrospective analysis of 417 percutaneous native renal biopsies.
• Patients with serum creatinine >1.5 mg/dL underwent either BT (n=51) or TEG (n=71).
• Desmopressin acetate (DDAVP) administration was considered for prolonged BT, abnormal TEG (low maximal amplitude), or suspected uremic thrombopathy.

Main Results:

• All 51 BT tests were normal; 34 of 71 TEG tests showed abnormalities, often combined.
• Abnormal TEG kinetics and maximal amplitude were linked to older age.
• Bleeding complications (6.23%) correlated with age, systolic blood pressure, and serum creatinine, not TEG results.

Conclusions:

• TEG abnormalities in renal dysfunction are diverse and do not predict bleeding risk during kidney biopsy.
• The utility of TEG in guiding hemostatic interventions before renal biopsy is questionable.
• Desmopressin acetate (DDAVP) administration should rely solely on clinical assessment, not TEG parameters.